CEA-Scan to get February review:
This article was originally published in Clinica
Executive Summary
The US FDA's Medical Imaging Drugs Advisory Committee (MIDAC) plans to review Immunomedics' CEA-Scan on February 16th. The Oncologic Drugs Advisory Committee deferred a decision on the colon-cancer imaging agent in October, saying MIDAC was a more relevant body to review the data (see Clinica No 678, p 19). The committee also criticised a lack of outcomes data and a failure to blind several investigators.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.